Xiaoyu Liu

Xiaoyu Liu

Auto-generated profile, based on publicly available information

Xiaoyu Liu

School of Pharmacy, Pharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, WI 53705, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2016 in Organic Letters
Verified
Journal Article
Closed access
XLXiaoyu Liu
Xiaoyu Liu
XJXiaozhen Jiao
Xiaozhen Jiao
HYHongguang Yang
Hongguang Yang
YYYangyang Yao
Yangyang Yao
PXPing Xie
Ping Xie

12 April 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
XCXufeng Cao
Xufeng Cao
DYDong Yang
Dong Yang
JPJyothi Parvathareddy
Jyothi Parvathareddy
YCYong-Kyu Chu
Yong-Kyu Chu
EKEun Jung Kim
Eun Jung Kim
JGJennifer E Golden
Jennifer E Golden
Venezuelan and eastern equine encephalitis viruses (VEEV and EEEV, respectively) are mosquito-borne, neuroinvasive human pathogens for which no FDA-approved therapeutic exists. Besides the biothreat posed by these viruses when aerosolized, arthropod transmission presents serious health risks to humans, as demonstrated by the 2019 outbreak of EEE disease in the United States that resulted in 38 confirmed cases, 19 deaths, and neurological effects in survivors. Here, we describe the discovery of a 2-pyrrolidinoquinazolinone scaffold, efficiently synthesized in two to five steps, whose structural optimization resulted in profound antiviral activity. The lead quinazolinone, BDGR-49, potently reduced cellular VEEV and EEEV titers by >7 log at 1 μM and exhibited suitable intravenous and oral pharmacokinetic profiles in BALB/c mice to achieve excellent brain exposure. Outstanding in vivo efficacy was observed in several lethal, subcutaneous infection mouse models using an 8-day dosing regimen. Prophylactically administered BDGR-49 at 25 mg kg −1 per day fully protected against a 10× LD 50 VEEV Trinidad donkey (TrD) challenge in BALB/c mice. Similarly, we observed 70% protection when 10× LD 50 EEEV FL93-939–infected C57BL/6 mice were treated prophylactically with BDGR-49 at 50 mg kg −1 per day. Last, we observed 100% therapeutic efficacy when mice, challenged with 10× LD 50 VEEV TrD, were dosed at 48 hours after infection with BDGR-49 at 25 mg kg −1 per day. Mouse brain viral titers at 96 hours after infection were reduced to values near the limit of detection. Collectively, these results underscore the substantial development potential of a well-tolerated, brain-penetrant lead compound that shows promise in preventing and treating encephalitic alphavirus disease.

1 June 2018 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
XLXiaoyu Liu
Xiaoyu Liu
PCPanpan Chen
Panpan Chen
XLXiaoyu Li
Xiaoyu Li
MBMingyu Ba
Mingyu Ba
XJXiaozhen Jiao
Xiaozhen Jiao
PXPing Xie
Ping Xie

1 November 2014 in Tetrahedron Letters
Verified
Journal Article
Closed access
XJXiaozhen Jiao
Xiaozhen Jiao
XLXiaoyu Liu
Xiaoyu Liu
CTChengsen Tian
Chengsen Tian
LDLiang Dong
Liang Dong
YYYangyang Yao
Yangyang Yao
PXPing Xie
Ping Xie